Microba Life Sciences Limited (ASX:MAP)

Market Cap	54.81M
Revenue (ttm)	15.67M
Net Income (ttm)	-14.94M
Shares Out	608.96M
EPS (ttm)	-0.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	249,788
Average Volume	491,571
Open	0.0910
Previous Close	0.0900
Day's Range	0.0910 - 0.0980
52-Week Range	0.0690 - 0.3250
Beta	2.37
RSI	63.35
Earnings Date	Jan 29, 2026

About Microba Life Sciences

Microba Life Sciences Limited provides microbiome testing, supplements, and analysis services in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, Asia, and Ireland. It operates in two segments, Testing Services and Supplements, and Research and Development. The company also develops pathology, therapeutics, and diagnostics services based on the human gut microbiome. In addition, it offers MetaPanel, a metagenomic test for pathogen detection; MetaXplore that provides a range of diagnostics solution...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2017
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: MAP

Financial Performance

In 2025, Microba Life Sciences's revenue was 15.67 million, an increase of 29.60% compared to the previous year's 12.09 million. Losses were -14.94 million, -25.07% less than in 2024.